{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:50:26Z","timestamp":1790808626596,"version":"4.1.0"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"\nBackground<\/jats:title>\nDisease\/patient registries are underutilized despite their multiple advantages over clinical trials in the clinical evaluation of drugs, such as the capacity for long-term curation, provision of patient outcome data in routine clinical practice, and provision of benchmark data for comparison. Ensuring the fit-for-purpose quality of data generated from such registries is important to informing regulatory decision making. Here, we report the construction of a quality management system aiming to ensure regulatory-grade data quality for a registry of Japanese patients with glaucoma to evaluate long-term patient outcomes.<\/jats:p>\n<\/jats:sec>\n\nMethods<\/jats:title>\nThe quality management system was established by reference to the risk-based approach in the ICH-E6 (R2) recommendations. The following three-component approach was taken: establishment of governance, computerized system validation (CSV), and implementation of risk assessment and control. Compliance of the system with the recommendations of regulatory guidelines relevant to use of the registry was assessed.<\/jats:p>\n<\/jats:sec>\n\nResults<\/jats:title>\nGovernance by academic collaboration was established. This was followed by the development of a total of 15 standard operating procedures, including CSV, data management, monitoring, audit, and management of imaging data. The data management system was constructed based on a data management plan, which specified data\/paper flow and data management procedures. The electronic data capture (EDC) system was audited by an external vendor, and configured and validated using the V-model framework as recommended in the GAMP5 guideline. Informed consent, eligibility assessment and major ophthalmology measurements were determined as Critical to Quality (CTQ) factors. A total of 22 risk items were identified and classified into three categories, and operationalized in the form of a risk control plan, which included training sessions and risk-based monitoring. The glaucoma registry addressed most quality recommendations in official guidelines issued by multiple health authorities, although two recommendations were not met.<\/jats:p>\n<\/jats:sec>\n\nConclusions<\/jats:title>\nWe established and configured a quality management system for a glaucoma registry to ensure fit-for-purpose data quality for regulatory use, and to curate long-term follow-up data of glaucoma patients in a prospective manner.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0286669","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T17:58:11Z","timestamp":1685728691000},"page":"e0286669","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["A quality management system aiming to ensure regulatory-grade data quality in a glaucoma registry"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1743-4473","authenticated-orcid":true,"given":"Shinsuke","family":"Wada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6913-9930","authenticated-orcid":true,"given":"Hisashi","family":"Urushihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"pone.0286669.ref001","unstructured":"GetReal initiatives. https:\/\/www.imi.europa.eu\/projects-results\/project-factsheets\/getreal-initiative."},{"key":"pone.0286669.ref002","unstructured":"Clinical Innovation Network. https:\/\/cinc.ncgm.go.jp."},{"issue":"4","key":"pone.0286669.ref003","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1310\/hpx5204-264","article-title":"21st Century Cures Act","volume":"52","author":"Michael Gabay","year":"2017","journal-title":"Hosp Pharm"},{"key":"pone.0286669.ref004","unstructured":"U.S. Food and Drug Administration. Use of Real-World Evidence to Support Regulatory Decision Making for Medical Devices. https:\/\/www.fda.gov\/media\/99447\/download."},{"key":"pone.0286669.ref005","unstructured":"European Medicines Agency. Discussion paper: Use of patient disease registries for regulatory purpose\u2014methodological and operational considerations. https:\/\/www.ema.europa.eu\/documents\/other\/discussion-paper-use-patient-disease-registries-regulatory-purposes-methodological-operational_en.docx."},{"key":"pone.0286669.ref006","unstructured":"Agency for Healthcare Research and Quality. Registries for Evaluating Patient Outcomes: A User\u2019s Guide: 4th Edition."},{"key":"pone.0286669.ref007","unstructured":"Ministry of Health, Labour and Welfare. Basic principles on Utilization of Registry for Applications. https:\/\/www.pmda.go.jp\/files\/000240810.pdf."},{"key":"pone.0286669.ref008","unstructured":"Ministry of Health, Labour and Welfare. Points to consider for Ensuring the Reliability in Utilization of Registry Data for Applications. https:\/\/www.pmda.go.jp\/files\/000240811.pdf."},{"key":"pone.0286669.ref009","unstructured":"International Conference on Harmonisation. ICH harmonised guideline integrated addendum to ICH E6(R1): Guideline for Good Clinical Practice ICH E6(R2) ICH Consensus Guideline. https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf."},{"key":"pone.0286669.ref010","unstructured":"The International Council for Harmonisation. ICH Reflection on \u201cGCP Renovation\u201d: Modernization of ICH E8 and Subsequent Renovation of ICH E6. https:\/\/admin.ich.org\/sites\/default\/files\/2021-05\/ICH_ReflectionPaper_GCPRenovation_2021_0519.pdf."},{"key":"pone.0286669.ref011","unstructured":"International Conference on Harmonisation. General consideration for clinical studies E8(R1). https:\/\/database.ich.org\/sites\/default\/files\/E8-R1_Guideline_Step4_2021_1006.pdf."},{"issue":"6","key":"pone.0286669.ref012","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1197\/jamia.M1087","article-title":"Defining and Improving Data Quality in Medical Registries: A Literature Review, Case Study, and Generic Framework","volume":"9","author":"DG Arts","year":"2002","journal-title":"J Am Med Inform Assoc"},{"key":"pone.0286669.ref013","unstructured":"U.S. Food and Drug Administration. SUMMARY REVIEW (BRINEURA). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761052Orig1s000SumR.pdf."},{"key":"pone.0286669.ref014","unstructured":"U.S. Food and Drug Administration. SUMMARY REVIEW (DEFITELIO). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208114Orig1s000SumR.pdf."},{"issue":"11","key":"pone.0286669.ref015","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"YC Tham","year":"2014","journal-title":"Ophthalmology"},{"issue":"18","key":"pone.0286669.ref016","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"RN Weinreb","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"pone.0286669.ref017","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s12325-016-0333-6","article-title":"Quality of Life in Glaucoma: A Review of the Literature","volume":"33","author":"L Quaranta","year":"2016","journal-title":"Adv Ther"},{"issue":"4","key":"pone.0286669.ref018","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/jnr.22800","article-title":"Critical role of calpain in axonal damage\u2010induced retinal ganglion cell death","volume":"90","author":"M Ryu","year":"2012","journal-title":"J Neurosci Res"},{"issue":"5","key":"pone.0286669.ref019","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/jnc.12325","article-title":"Critical role of Nrf2 in oxidative stress-induced retinal ganglion cell death","volume":"127","author":"N Himori","year":"2013","journal-title":"J Neurochem"},{"issue":"4","key":"pone.0286669.ref020","doi-asserted-by":"crossref","first-page":"e00096","DOI":"10.1016\/j.heliyon.2016.e00096","article-title":"Neuroprotective effects of VCP modulators in mouse models of glaucoma","volume":"2","author":"N Nakano","year":"2016","journal-title":"Heliyon"},{"key":"pone.0286669.ref021","unstructured":"International Society for Pharmaceutical Engineering. A Risk-Based Approach to Compliant GxP Systems GAMP5."},{"key":"pone.0286669.ref022","unstructured":"Ministry of Health, Labour and Welfare. Using electromagnetic records and electronic signatures for application for approval or licensing of drugs. https:\/\/www.pmda.go.jp\/files\/000158308.pdf (in Japanese)."},{"key":"pone.0286669.ref023","unstructured":"Transcelerate. Risk Based Monitoring Solutions. https:\/\/www.transceleratebiopharmainc.com\/assets\/risk-based-monitoring-solutions\/."},{"key":"pone.0286669.ref024","unstructured":"International Medical Device Regulators Forum. Tools for Assessing the Usability of Registries in Support of Regulatory Decision-Making. http:\/\/www.imdrf.org\/docs\/imdrf\/final\/technical\/imdrf-tech-180327-usability-tools-n46.pdf."},{"key":"pone.0286669.ref025","unstructured":"Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labour and Welfare, and Ministry of Economy, Trade and Industry. Ethical guidelines for medical and biological research involving human subjects. https:\/\/www.mhlw.go.jp\/content\/000909926.pdf. (in Japanese)."},{"key":"pone.0286669.ref026","unstructured":"CDISC. https:\/\/www.cdisc.org\/standards\/foundational\/cdash."},{"key":"pone.0286669.ref027","unstructured":"MedDRA. https:\/\/www.meddra.org\/"},{"key":"pone.0286669.ref028","unstructured":"WHO Drug Dictionary. https:\/\/who-umc.org\/whodrug\/"},{"issue":"7","key":"pone.0286669.ref029","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/pds.4004","article-title":"Evidence generation from healthcare databases: recommendations for managing change","volume":"25","author":"A Bourke","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0286669","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T17:58:28Z","timestamp":1685728708000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0286669"}},"subtitle":[],"editor":[{"given":"Simon","family":"Grima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0286669","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]}}}